50 results
Page 2 of 3
6-K
EX-99.1
ignzaf z9v7
1 Mar 21
Current report (foreign)
12:00am
424B5
ahd1kbk5g
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
drls0gz0p3sdon 2w
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
ht9isf1nr8m1dxd
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
wtpyqu3
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
424B5
jxrlc
20 Jul 20
Prospectus supplement for primary offering
9:21am
6-K
EX-99.1
i776e aklc3t
20 Jul 20
from 6-K
9:02am
F-3
mkwhrp 920t6g4r687b
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.1
mxbi56lxey u73iva
9 Apr 20
Controlling inflammation LIFESCI CAPITAL ALPHA SERIES CONFERENCE 2020
7:26am
6-K
EX-99.2
kjrhb2bkl1x eesz
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.3
kyq405vafpebi86
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.1
2kldscz2z29a8r vogdz
16 Jan 20
CONTROLLING INFLAMMATION JP Morgan Corporate Presentation January 2020
4:11pm
6-K
EX-99.1
nmfu28g
14 Nov 19
Current report (foreign)
4:10pm
6-K
EX-99.1
yyljb6m30yy64eqhh
8 May 19
IFX-1 C5a Controlling inflammation Corporate Presentation May 2019
6:02am